Advertisement
MCP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/mcp.M300066-MCP200 on October 26, 2003.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M300066-MCP200v1
3/1/66    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Glossary
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimmermann-Ivol, C. G.
Right arrow Articles by Sanchez, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimmermann-Ivol, C. G.
Right arrow Articles by Sanchez, J.-C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular & Cellular Proteomics 3:66-72, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.

Research

Fatty Acid Binding Protein as a Serum Marker for the Early Diagnosis of Stroke

A Pilot Study*

Catherine G. Zimmermann-Ivol{ddagger}, Pierre R. Burkhard§, Josette Le Floch-Rohr§, Laure Allard{ddagger}, Denis F. Hochstrasser{ddagger} and Jean-Charles Sanchez{ddagger},¶

From the {ddagger} Biomedical Proteomics Research Group, Clinical Chemistry Laboratory, Geneva University Hospital, Geneva, Switzerland, and § Department of Neurology, Geneva University Hospital, Geneva, Switzerland

No biological marker is currently available for the routine diagnosis of stroke. The aim of this pilot study was to determine whether heart-fatty acid binding protein (H-FABP) could be used as a valid diagnostic biomarker for stroke, as compared with neuron-specific enolase (NSE) and S100B proteins. Using two-dimensional gel electrophoresis separation of cerebrospinal fluid proteins and mass spectrometry techniques, FABP was found elevated in the cerebrospinal fluid of deceased patients, used as a model of massive brain damage. Because H-FABP, a FABP form present in many organs, is also localized in the brain, an enzyme-linked immunosorbant assay was developed to detect H-FABP in stroke versus control plasma samples. However, H-FABP being also a marker of acute myocardial infarction (AMI), troponin-I and creatine kinase-MB levels were assayed at the same time in order to exclude any concomitant heart damage. NSE and S100B levels were assayed simultaneously. These assays were assessed in serial plasma samples from 22 control patients with no AMI or stroke, 20 patients with AMI but no stroke, and 22 patients with an acute stroke but no AMI. Twenty-two out of the 22 control patients and 15 out of the 22 stroke patients were correctly classified, figures much better than those obtained with NSE or S100B, in the same study’s population. H-FABP appears to be a valid serum biomarker for the early diagnosis of stroke. Further studies on large cohorts of patients are warranted.

To whom correspondence should be addressed: Biomedical Proteomics Research Group, Laboratoire Central de Chimie Clinique, Hôpital Universitaire de Genève, 24, rue Micheli-du-Crest, 1211 Geneva 14, Switzerland. Tel.: +41-22-372-73-74; Fax: +41-22-372-73-99; E-mail: sanchez{at}dim.hcuge.ch


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
J.-M. Lee, K. Blennow, N. Andreasen, O. Laterza, V. Modur, J. Olander, F. Gao, M. Ohlendorf, and J. H. Ladenson
The Brain Injury Biomarker VLP-1 Is Increased in the Cerebrospinal Fluid of Alzheimer Disease Patients
Clin. Chem., October 1, 2008; 54(10): 1617 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
W. Whiteley, M.-C. Tseng, and P. Sandercock
Blood Biomarkers in the Diagnosis of Ischemic Stroke: A Systematic Review
Stroke, October 1, 2008; 39(10): 2902 - 2909.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. J. Finehout, Z. Franck, N. Relkin, and K. H. Lee
Proteomic Analysis of Cerebrospinal Fluid Changes Related to Postmortem Interval
Clin. Chem., October 1, 2006; 52(10): 1906 - 1913.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. Allard, P. R. Burkhard, P. Lescuyer, J. A. Burgess, N. Walter, D. F. Hochstrasser, and J.-C. Sanchez
PARK7 and Nucleoside Diphosphate Kinase A as Plasma Markers for the Early Diagnosis of Stroke
Clin. Chem., November 1, 2005; 51(11): 2043 - 2051.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement